1Mes·

Evotec Q32024 $EVT (+1,61%)

attachment




Financial performance:

  • Revenues: Group revenues decreased by 1 % to EUR 575.7 m in the first nine months of 2024 compared to EUR 580.1 m in the previous year. This was mainly due to a 12% decline in the Shared R&D segment, while Just-Evotec Biologics revenues increased by an impressive 74% to EUR 128.7 million.
  • Net profit: Net loss increased to EUR 155.2 million, compared to EUR 67.8 million in the previous year, due to increased cost of sales and restructuring costs.
  • Adjusted EBITDA: The Group's adjusted EBITDA fell to -6.0 million euros, compared to 50.2 million euros in the previous year. The main reasons for this were a discrepancy between sales and the cost base in the Shared R&D segment as well as costs for the expansion of Just-Evotec Biologics.


Balance sheet overview:

  • Total assets: Total assets decreased by EUR 261.7 million to EUR 1,990.8 million as of September 30, 2024.
  • Total liabilities: Current liabilities decreased to 333.6 million euros, compared to 464.6 million euros in the previous year. Non-current liabilities decreased slightly to 688.7 million euros, compared to 667.9 million euros.
  • Equity: Equity decreased by 151.4 million euros to 968.5 million euros.


Profit and loss account:

  • Gross profit: Gross profit fell to 68.8 million euros, with a gross margin of 11.9%, compared to 23.7% in the previous year.
  • Operating expenses: Operating expenses increased to 218.1 million euros, compared to 173.3 million euros in the previous year.


Cash flow overview:

  • Operating activities: Net cash flow from operating activities was negative at -56.0 million euros, compared to a positive cash flow of 16.5 million euros in the previous year.
  • Investment activities: Net cash flow used in investing activities amounted to EUR -88.1 million, mainly due to investments in Just-Evotec Biologics.
  • Financing activities: Net cash flow amounted to EUR -132.1 million due to repayments of loans and lease obligations.


Key figures and profitability metrics:

  • Equity ratio: Down slightly to 48.6%, compared to 49.7% in the previous year.


Segment information:

  • Shared R&D: Revenue decreased by 12 % to EUR 447.1 million, with a gross margin of 14.3 %.
  • Just-Evotec Biologics: Revenues increased by 74 % to EUR 128.7 million, with an improved gross margin of 3.8 %.


Competitive position:

  • Strategic partnerships: Successful expansions and new collaborations with Sandoz, BMS and a new partnership with Novo Nordisk in cell therapy.


Forecasts and management commentary:

  • Outlook: Guidance confirmed despite challenging market conditions.


Risks and opportunities:

  • Restructuring costs: These amounted to EUR 62.3 million, due to planned staff reductions and site closures.
  • Market conditions: Persistently weak market and overcapacity adversely affect results.


Summary of results:


Positive aspects:

  • Strong sales growth of 74 % at Just-Evotec Biologics.
  • Successful strategic partnerships with Sandoz, BMS and Novo Nordisk.
  • Expansion of operations with the opening of the J.POD facility in Toulouse, France.
  • Cost reduction in R&D expenditure by 15 %.
  • Improved gross margin of Just-Evotec Biologics to 3.8 %.


Negative aspects:

  • Decrease in Group revenues by 1 %.
  • Sharp increase in net loss to 155.2 million euros.
  • Decrease in gross margin to 11.9%.
  • 8% increase in operating expenses, in particular SG&A costs.
  • Challenges in cash flow from operating and investing activities.
4
3 Commenti

immagine del profilo
I have a few in my portfolio and am speculating on the 20. Let's see, they are actually neither fish nor fowl. Do they now want to research and develop or do they want to produce basic materials?
1
Visualizza tutti 2 ulteriori risposte
Partecipa alla conversazione